Onco360 Appoints Paul Jardina as President and Chief Executive Officer

Jardina Brings More Than 20 Years of Healthcare Industry Experience to Onco360

NEW YORK--()--Onco360, one of the nation’s largest independent providers of oncology pharmacy services, today announced that Paul Jardina has been named President and Chief Executive Officer.

“Onco360 is a clear leader in oncology pharmacy care, with growing scale and the unique ability to service the localized needs of community- and hospital based-oncologists across the country”

Mr. Jardina has more than 20 years of healthcare industry experience as an executive in oncology and physician services. Most recently he served as President and CEO of U.S. Physiatry, a physician services company focused on physical medicine and rehabilitation in the post-acute continuum. Mr. Jardina has served in various leadership positions for U.S. Oncology (now McKesson Specialty Health), leading key business lines, including oncology specialty pharmacy, drug distribution, and radiation and imaging. In his role at U.S. Oncology, Mr. Jardina was instrumental in the development and growth of the company’s pharmaceutical service lines and its transition to an open market provider of oncology pharmaceutical services.

“Onco360 is a clear leader in oncology pharmacy care, with growing scale and the unique ability to service the localized needs of community- and hospital based-oncologists across the country,” said Mr. Jardina. “I am honored to join the Company at this time of tremendous opportunity, and have already begun working with the talented team at Onco360 to further leverage Onco360’s robust care platform in order to provide even more patients with the best oncology care possible. I am excited to position the Company for its next phase of growth and development.”

Greg Weishar, CEO of PharMerica, a significant investor in Onco360, said, “We are confident that Paul is the right leader to take Onco360 forward. His deep experience in healthcare and oncology make him the ideal CEO for Onco360. We are confident that, under his leadership, Onco360 will continue to fulfill its mission of transforming oncology pharmacy, now and in the future.”

Burt Zweigenhaft will continue to serve as the Company’s Vice Chairman and Chief Strategy Officer. In this capacity, Mr. Zweigenhaft will focus on key strategic initiatives and business development to further support the Company’s growth strategy.

About Onco360® Oncology Pharmacy Solutions:

With executive offices in New York City, Onco360 (http://onco360.com) is the largest independent provider of Oncology Pharmacy services in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. The company’s clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients. Onco360 is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and the clinical experience and expertise that comes from its focus in oncology. Onco360 dispenses through its network JCAHO-accredited Oncology Pharmacies. PharMerica Corporation (NYSE:PMC), a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, made a significant strategic investment in Onco360. The partnership between PharMerica and Onco360 creates the only national oncology pharmacy and care management platform in the country, with the unique ability to service the localized needs of community- and hospital based-oncologists.

Contacts

Onco360
Amvrosios Ioannidis, 646-356-7705
M: 516-492-2557
amvrosiosi@Onco360.com

Recent Stories

  • KKR Completes Acquisition of PharMerica
    December 07, 2017
    LOUISVILLE, Ky.--(EON: Enhanced Online News)--PharMerica Corporation (NYSE:PMC) today announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an a... more »
  • PharMerica Reports Third Quarter 2017 Results
    November 09, 2017
    LOUISVILLE, Ky.--(EON: Enhanced Online News)--PharMerica Corporation (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today repor... more »
  • PharMerica Announces Approval of Merger by Stockholders
    November 09, 2017
    LOUISVILLE, Ky.--(EON: Enhanced Online News)--PharMerica Corporation (NYSE: PMC), announced that at its special meeting of stockholders held today, a majority of the outstanding shares of PharMeric... more »
RSS feed for Onco360

Onco360